Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1829613 | 1.00 | MDM4 (0.52) | MDM4TP53PTPN1CASP3KMT2A | |
| SCHEMBL31688826 | 0.97 | MDM4 (0.52) | MDM4TP53PTPN1CASP3KMT2A | |
| SCHEMBL31080757 | 0.97 | MDM4 (0.52) | MDM4TP53PTPN1CASP3KMT2A | |
| SCHEMBL7056250 | 0.92 | MDM4 (0.51) | MDM4TP53PTPN1CASP3KMT2A | |
| SCHEMBL7316241 | 0.91 | MDM4 (0.54) | MDM4TP53PTPN1CASP3KMT2A | |
| SCHEMBL10622470 | 0.90 | MDM4 (0.53) | MDM4TP53CASP3KMT2ATLR2 | |
| SCHEMBL119699 | 0.90 | MDM4 (0.53) | MDM4TP53CASP3KMT2ATLR2 | |
| SCHEMBL29402444 | 0.90 | MDM4 (0.53) | MDM4TP53CASP3KMT2ATLR2 | |
| SCHEMBL29398558 | 0.90 | MDM4 (0.53) | MDM4TP53CASP3KMT2ATLR2 | |
| SCHEMBL119472 | 0.90 | MDM4 (0.53) | MDM4TP53CASP3KMT2ATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | claimed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| EP-2275105-B1 | Heterocyclic derivatives as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-05 | — | — | EP | disclosed |
| EP-1499313-B1 | HETEROCYCLIC DERIVATIVES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-29 | — | — | EP | disclosed |
| EP-2275105-A1 | Heterocyclic derivatives as opioid receptor modulators | Janssen Pharmaceutica NV (BE) | 2011-01-19 | — | — | EP | disclosed |
| US-7659402-B2 | use as pain relievers, gastrointestinal disorders; 2-Amino-3-aryl-1-[3-((hetero)aryl)piperidin-1-yl]-propan-1-one compounds | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-09 | — | — | US | disclosed |
| CN-101175726-A | Process for the preparation of opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-07 | — | — | CN | disclosed |
| EP-1863764-A1 | PROCESS FOR THE PREPARATION OF OPIOID MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2007-12-12 | — | — | EP | disclosed |
| US-7202381-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2007-04-10 | — | — | US | disclosed |
| WO-2006098982-A1 | PROCESS FOR THE PREPARATION OF OPIOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-21 | — | — | WO | disclosed |
| US-20060211861-A1 | Process for the preparation of opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-21 | — | — | US | disclosed |
| US-7041681-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-09 | — | — | US | disclosed |
| US-20060030558-A1 | Novel compounds as opioid receptor modulators | BRESLIN HENRY J | 2006-02-09 | — | — | US | disclosed |
| US-20050187252-A1 | 2-Amino-3-(4-hydroxy-phenyl)-1-[2-(5-phenyl-oxazol-2-yl)-piperidin-1-yl]-propan-1-one; pain and gastrointestinal disorders | BRESLIN HENRY J (US) | 2005-08-25 | — | — | US | disclosed |
| EP-1499313-A2 | HETEROCYCLIC DERIVATIVES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-26 | — | — | EP | disclosed |
| US-20040010014-A1 | Novel compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2004-01-15 | — | — | US | disclosed |
| WO-2003092688-A2 | HETEROCYCLIC DERIVATIVES AS OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030558-A1 | Novel compounds as opioid receptor modulators | OPRL1, OPRK1, OPRM1 | MDM4 4706/4885TP53 4868/4885PTPN1 3177/4885 |
| US-20060211861-A1 | Process for the preparation of opioid modulators | OPRM1, OPRK1, OPRL1 | MDM4 4685/4885TP53 4877/4885PTPN1 3530/4885 |
| US-20050187252-A1 | 2-Amino-3-(4-hydroxy-phenyl)-1-[2-(5-phenyl-oxazol-2-yl)-piperidin-1-yl]-propan-1-one; pain and gastrointestinal disorders | OPRL1, OPRK1, OPRD1 | MDM4 4766/4885TP53 4872/4885PTPN1 2798/4885 |
| US-20040010014-A1 | Novel compounds as opioid receptor modulators | OPRL1, OPRK1, OPRM1 | MDM4 4706/4885TP53 4868/4885PTPN1 3177/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | MDM4 1648/4885TP53 614/4885PTPN1 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.